Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,640
Open 24.01
Bid (Size) 23.69 (100)
Ask (Size) 24.00 (500)
Prev. Close 24.01
Today's Range 24.01 - 24.01
52wk Range 8.290 - 27.08
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+64.9%
+64.9%
1 Month
+21.5%
+21.5%
3 Month
+56.7%
+56.7%
6 Month
+67.7%
+67.7%
1 Year
+175.3%
+175.3%

More News

Read More
Earnings Scheduled For October 28, 2025
Via Benzinga
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's session
Via Chartmill
Arcutis Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Falls Over 2%; PayPal Shares Spike Higher
Via Benzinga
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today
Via The Motley Fool
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise.
Via Investor's Business Daily
Traders are paying attention to the gapping stocks in Tuesday's session.
Via Chartmill
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability
Via Chartmill
Topics Earnings
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview
Via Benzinga
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Technical Strength with High Growth Momentum
Via Chartmill
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
Top 5 Biotech Stocks With Strong Momentum
Via Benzinga

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
The current price of Arcutis Biotherapeutics, Inc. - Common stock is 24.01
When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 11/04/25 04:00 PM ET
What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.21B
How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.